Scholarlink

Background <p>Although cancer and atherosclerosis are based on shared risk factors, the impact of the acute coronary syndrome (ACS) on long-term survival in cancer patients is still unclear.</p> Methods <p>We retrospectively analyzed 441 patients with initial diagnosis of cancer prior to ACS who were subjected to cardiac catheterization (CC) with a follow-up of at median 4.78 years (IQR: 0.58–9.33). These patients were compared to non-cancer ACS patients via propensity score matching according to the cardiac risk factors age, sex, arterial hypertension and diabetes.</p> Results <p>We found ACS, and overall Non-ST-elevation myocardial infarction (NSTEMI), as a relevant predictor of outcome in cancer patients with the highest mortality rates (88 deaths (40%) in non-cancer patients with NSTEMI vs. 174 deaths (64.9%), in the respective cancer patients <i>p</i> &lt; 0.001). In multivariable COX models including other comorbidities, cancer was found to independently influence mortality as well as cardiovascular hospital readmission (HR all-cause mortality: 1.47, <i>p</i> &lt; 0.001, HR readmission: 1.54, <i>p</i> &lt; 0.001). Other risk factors, such as renal dysfunction, diabetes or impaired left ventricular function showed comparable influence on mortality. Percutaneous coronary intervention (PCI) rates did not differ between the groups (228/441 non-cancer patients (51.7%) vs. 227/441 cancer patients (51.5%), <i>p</i> = 0.95), but optimized medical treatment was less present in the cancer group.</p> <p>In a subgroup of cancer patients with available biomarker data, NT-proBNP, but not hs-cTnT, was found to be useful for risk stratification (HR univariate: 1.28, HR multivariate considering risk factors and hs-cTnT: 1.26, <i>p</i> &lt; 0.001 .</p> Conclusions <p>Our data indicate a relevant effect of ACS, especially NSTEMI, in cancer patients with impact on long-term mortality and cardiac morbidity. Cancer patients with NSTEMI warrant special care, considering comorbidities and optimized medical treatment of the cardiac disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The impact of acute coronary syndrome on long-term survival in cancer patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月7日

查看全文
  • Daniel Finke,
  • Markus B. Heckmann,
  • Jessica M. Schug,
  • Lukas F. Entenmann,
  • Hauke Hund,
  • Hugo A. Katus,
  • Norbert Frey,
  • Lorenz H. Lehmann

摘要

Background

Although cancer and atherosclerosis are based on shared risk factors, the impact of the acute coronary syndrome (ACS) on long-term survival in cancer patients is still unclear.

Methods

We retrospectively analyzed 441 patients with initial diagnosis of cancer prior to ACS who were subjected to cardiac catheterization (CC) with a follow-up of at median 4.78 years (IQR: 0.58–9.33). These patients were compared to non-cancer ACS patients via propensity score matching according to the cardiac risk factors age, sex, arterial hypertension and diabetes.

Results

We found ACS, and overall Non-ST-elevation myocardial infarction (NSTEMI), as a relevant predictor of outcome in cancer patients with the highest mortality rates (88 deaths (40%) in non-cancer patients with NSTEMI vs. 174 deaths (64.9%), in the respective cancer patients p < 0.001). In multivariable COX models including other comorbidities, cancer was found to independently influence mortality as well as cardiovascular hospital readmission (HR all-cause mortality: 1.47, p < 0.001, HR readmission: 1.54, p < 0.001). Other risk factors, such as renal dysfunction, diabetes or impaired left ventricular function showed comparable influence on mortality. Percutaneous coronary intervention (PCI) rates did not differ between the groups (228/441 non-cancer patients (51.7%) vs. 227/441 cancer patients (51.5%), p = 0.95), but optimized medical treatment was less present in the cancer group.

In a subgroup of cancer patients with available biomarker data, NT-proBNP, but not hs-cTnT, was found to be useful for risk stratification (HR univariate: 1.28, HR multivariate considering risk factors and hs-cTnT: 1.26, p < 0.001 .

Conclusions

Our data indicate a relevant effect of ACS, especially NSTEMI, in cancer patients with impact on long-term mortality and cardiac morbidity. Cancer patients with NSTEMI warrant special care, considering comorbidities and optimized medical treatment of the cardiac disease.